Mass General Brigham researchers published preclinical data showing engineered tumor cells can be leveraged to restore innate immune sensing and trigger robust antitumor responses in animal models. The approach restores a suppressed pathway within tumor cells to activate immune recruitment and cytotoxic activity. Data, reported in a peer‑reviewed outlet, demonstrate tumor‑intrinsic modulation of innate immune signaling can convert immunologically “cold” tumors into ones that attract effector cells. The team highlights implications for combination strategies with checkpoint inhibitors and cellular therapies. This preclinical finding provides a potential translational route to overcome tumor immune evasion mechanisms; the authors called for rapid advancement into translational studies to test safety and synergy with existing immunotherapies.